Cell Therapy News Volume 25.33 | Oct 28 2024

    0
    64








    2024-10-28 | CTN 25.33


    Cell Therapy News by STEMCELL Technologies
    Vol. 25.33 – 28 October, 2024
    TOP STORY

    Long-Term Lineage Commitment in Hematopoietic Stem Cell Gene Therapy

    Investigators analyzed hematopoietic reconstitution in 53 patients treated with lentiviral-HSC-gene therapy for diverse conditions such as metachromatic leukodystrophy, Wiskott-Aldrich syndrome, and β-thalassemia over a follow-up period of up to eight years, using vector integration sites as markers of clonal identity.
    [Nature]

    Full Article
    PUBLICATIONSListed by the impact factor of the journal

    Programmable Bacteria Synergize with PD-1 Blockade to Overcome Cancer Cell–Intrinsic Immune Resistance Mechanisms

    The authors engineered a strain of probiotic bacteria that homed to tumors and locally released IFN-γ. A single intratumoral injection of these IFN-γ–producing bacteria was sufficient to drive systemic tumor antigen–specific antitumor immunity, without observable toxicity.
    [Science Immunology]

    Full Article

    Antibiotic-Induced Loss of Gut Microbiome Metabolic Output Correlates with Clinical Responses to CAR T Cell Therapy

    Investigators observed that prior exposure to broad-spectrum ABX with extended anerobic coverage like piperacillin-tazobactam and meropenem was associated with worsened anti-CD19 CAR-T therapy survival outcomes in large B cell lymphoma patients, compared to other ABX classes.
    [Blood]

    Abstract

    Widespread Gene Editing in the Brain via In Utero Delivery of mRNA Using Acid-Degradable Lipid Nanoparticles

    The authors demonstrated that in utero intracerebroventricular injection of densely PEGylated lipid nanoparticles containing an acid-degradable PEG–lipid could safely and effectively deliver mRNA for gene editing enzymes to the fetal mouse brain, resulting in successful transfection and editing of brain cells.
    [ACS Nano]

    Full Article

    Anti-CD19 CAR-T Cells Are Effective in Severe Idiopathic Lambert-Eaton Myasthenic Syndrome

    Scientists reported a patient with isolated idiopathic Lambert-Eaton myasthenic syndrome treated with autologous anti-CD19-CAR-T cells.
    [Cell Reports Medicine]

    Full ArticleGraphical Abstract

    Matrix-Bound Nanovesicles Alleviate Particulate-Induced Periprosthetic Osteolysis

    The authors investigated the effects of matrix-bound nanovesicles (MBVs) on receptor activator of nuclear factor κΒ ligand-induced osteoclast formation in vitro and particulate-induced osteolysis in vivo.
    [Science Advances]

    Full Article

    CD27-Armored BCMA CAR T Cell Therapy (CBG-002) for Relapsed and Refractory Multiple Myeloma: A Phase I Clinical Trial

    Scientists investigated the feasibility of CBG-002, an CD27-armored BCMA CAR T therapy, to improve clinical efficacy in patients with refractory multiple myeloma.
    [Cancer Immunology Research]

    Abstract

    Histone Modifications and Sp1 Promote GPR160 Expression in Bone Cancer Pain within Rodent Models

    The authors profile orphan G protein-coupled receptors in the dorsal root ganglia following tumor infiltration, and observed a notable increase in GPR160 expression.
    [EMBO Reports]

    Full ArticleGraphical Abstract

    Cationized Extracellular Vesicles for Gene Delivery

    Stable, small size cationized extracellular vesicles (EVs) were loaded with plasmid DNA, or mRNA, or siRNA. Nucleic acid loaded EVs were efficiently taken up by target cells as demonstrated by confocal microscopy and delivered their cargo to the nuclei in triple negative breast cancer cells and macrophages.
    [Scientific Reports]

    Full Article
    Image of man completing the on-demand CFU assay course on his laptop.
    REVIEWS

    Advances and Applications of RNA Vaccines in Tumor Treatment

    Different RNA vaccine platforms for different tumors have shown encouraging results in animal and human models. The authors comprehensively describe the advances and applications of RNA vaccines in antitumor therapy.
    [Molecular Cancer]

    Full ArticleGraphical Abstract

    Research Advances of Cellular Nanoparticles as Multiplex Countermeasures

    Scientists trace the research advances of cellular nanoparticles technology as multiplex countermeasures across four categories with progressive functions.
    [ACS Nano]

    Full Article

    Exosome-Based Cell Therapy for Diabetic Foot Ulcers: Present and Prospect

    Investigators summarize the role and mechanisms of exosomes from diverse cellular sources in diabetic wound healing research.
    [Heliyon]

    Full Article
    INDUSTRY AND POLICY NEWS

    Do Stem Cell Transplants Increase Cancer Risk? Long-Lived Recipients Offer Clues

    People who have received transplants for blood cancer, some more than 40 years ago, do not have high rates of potentially cancer-causing mutations.
    [Nature News]

    Press Release

    $430 Million Cell and Gene Therapy Center Is Coming to Long Island. Here’s More on New York Biogenesis Park.

    Governor Kathy Hochul on Tuesday announced a $150 million investment in a new state-of-the-art cell and gene therapy hub to be built on Long Island.
    [CBS News]

    Press Release

    $1.8 Million Awarded to Study the Durability of Gene Therapy

    The National Institutes of Health awarded assistant professor of biomedical engineering Christopher Nelson a little more than $1.8 million to study the long-term efficacy of gene therapy. The five-year award will be used to consider the genetic and cellular determinants that may be limiting the success of new gene therapies.
    [University of Arkansas]

    Full Article
    FEATURED EVENT

    2nd Cell Therapy for Autoimmune Disease Summit

    December 2-4, 2024
    Philadelphia, Pennsylvania, United States

    > See All Events

    JOB OPPORTUNITIES

    Research Fellow – Gene Therapy for Rare Epilepsy

    University College London – London, England, United States

    PhD Studentship – Hematopoietic Specification

    Norwich Bioscience Institutes – Norwich, England, United Kingdom

    Research Associate – Self-Renewing Macrophages in Tumor Biology

    TU Dresden – Dresden, Germany

    Professor – Biomedical Engineering

    University of Wisconsin Madison – Madison, Wisconsin, United States

    Senior Scientist – Cellular Therapy Safety Testing

    Bristol-Myers Squibb – Seattle, Washington, United States

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2